Limenbio Generates Significant International Interest at CRYO 2025

2025-07-28 15:22 All news

We're proud to announce our successful participation in CRYO 2025, held in Hanover, Germany, from July 22–25. Our team presented our proprietary organ and tissue preservation technology, which captured the rapt attention of leading academics and industry players, opening promising pathways for future collaboration.

The annual CRYO conference, organized by the Society for Cryobiology since 1964, is the world's premier event dedicated to low-temperature biology and medicine. It convenes the brightest minds from academic institutions and cutting-edge biotech firms to share advancements in preserving biological systems—from single cells and reproductive materials to complex organs.We are proud to announce our successful participation in CRYO2025 held in Hanover, Germany from July 22-25. We’ve presented our organ and tissue preservation technology, capturing the focused attention of leading academics and industry players and securing promising pathways for future collaboration.

Validation on the Global Stage

For Limenbio, attendance at CRYO 2025 served as a crucial mark of scientific validation. Our presence was not incidental; our submitted abstracts underwent a rigorous peer-review process and were accepted for a poster presentation.

"We were invited because our work resonated with the conference organizers. Our research passed the review and was deemed compelling enough to share with the community," noted Arkadiy Ivanov, Co-founder and Head of Business Development. "That, in itself, was our first success."

Unprecedented Engagement Signals Strong Interest

At many scientific conferences, poster sessions are quiet affairs, with the expectation of engaging only a handful of interested parties. Limenbio shattered this expectation.

"Our poster detailing our successful experiments on rat models became a major focal point," shared Alexandr Ponomarev, Co-founder and Head of Technology Development. "While one typically expects two to four visitors, we consistently had a crowd around us, fielding at least seven to ten serious inquiries during the dedicated session." He added, "The level of engagement was markedly higher than my previous experience at CRYO 2016. This time, working alongside Arkadiy, we were constantly busy."

The interest extended beyond the physical hall. Our digital poster, uploaded to the conference's accompanying app, was among the most frequently visited by online participants, further amplifying the reach of Limenbio's technology.

Technology Driving Dialogue and Collaboration

The questions from attendees were not superficial; they were deeply technical and pointed toward practical application. Visitors probed the scientific rigor of the experiments, the specifics of the technology, and—most importantly—potential collaboration models.

"Many immediately asked, 'How can we work with you?' They discussed taking our findings back to their supervisors to explore collaboration," explained Alexandr Ponomarev.

The conference served as a powerful networking engine, generating several high-value contacts that are already evolving into concrete discussions:

A Leading U.S. University (Texas): Exploring fundamental research collaborations and potential educational opportunities.
A German Research Institute (Nuremberg): Investigating the use of Limenbio's technology as an intermediate step in their pioneering work on cryopreserving brain neural tissue.
A UK-based Biotech Company: Specializing in the preservation of oocyte-cumulus complexes for fertility treatments. Integrating Limenbio's approach, their initial results suggest, could significantly improve their outcomes, particularly for ovarian tissue preservation.

Strategic Takeaways and the Road Ahead

Beyond the immediate contacts, the conference provided invaluable strategic insights for Limenbio's future direction.

"We received confirmation that we are on the right track," stated Arkadiy Ivanov. "We are working on something that is both interesting and highly promising. In a deep-tech startup, you constantly need validation that you're heading in the right direction. The interest from participants and the overall activity in the community confirmed that our technology is truly world-class."

A critical takeaway was the absence of direct competitors. Limenbio’s unique approach to preservation occupies a distinct and unclaimed niche. However, the keen interest from adjacent fields signals that the window of opportunity is now.

"It means we need to accelerate our efforts, bring our product to market more quickly, and establish our leadership position," Arkadiy Ivanov emphasized.

The team also identified key industry trends:

The Dominance of Assisted Reproductive Technology (ART): Over 50% of presentations focused on human applications, particularly the preservation of embryos, oocytes, and genetic material.
The Focus on Rewarming: A significant number of talks addressed the critical challenge of thawing/rewarming, which is just as vital as the cooling process itself.
The AI Buzz: Artificial intelligence was a major talking point, primarily used for tasks like optimizing cryoprotectant cocktail formulas. While noting its potential, the team maintains a focused, practical approach to its core technology.

Next Steps: From Hanover to Global Market

The conclusion for the Limenbio team is clear: this is only the beginning.

"The main takeaway is that we must continue this momentum," Alexander Ponomarev stated. "The contacts we made are tangible, and we are already scheduling follow-up meetings."

The immediate plan is to diligently nurture the connections forged at CRYO 2025. In the future, we plan to participate in more commercially focused industry events to broaden the market dialogue and accelerate our trajectory of global engagement.

Limenbio's successful outing at CRYO 2025 is more than a conference summary; it is a testament to a deep-tech startup arriving on the world stage with a validated, sought-after technology, ready to transform the future of bioscience and medicine.